Aveo raises another $100M, as tivozanib goes head-to-head with Nexavar in RCC
This article was originally published in Scrip
Executive Summary
Cancer developer Aveo Pharmaceuticals on 15 June priced a public offering of 5.75 million shares of its common stock at $17.50 per share for proceeds of $100.6 million.